{"id":"treatment-of-tki-in-cml","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Myelosuppression"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BCR-ABL is a fusion protein resulting from a chromosomal abnormality in CML cells. By inhibiting this protein, the drug effectively blocks the proliferation of cancer cells.","oneSentence":"This drug targets the BCR-ABL protein to inhibit cancer cell growth in chronic myeloid leukemia.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:01.234Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic myeloid leukemia (CML) treatment"}]},"trialDetails":[{"nctId":"NCT07493408","phase":"PHASE2","title":"Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML","status":"NOT_YET_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2026-03-30","conditions":"Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL)","enrollment":45},{"nctId":"NCT07489755","phase":"PHASE3","title":"TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients","status":"NOT_YET_RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2026-04-01","conditions":"Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia - Chronic Phase","enrollment":180},{"nctId":"NCT07354074","phase":"PHASE2","title":"Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-05-04","conditions":"Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, Philadelphia Chromosome Positive","enrollment":50},{"nctId":"NCT05143840","phase":"PHASE2","title":"Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"RECRUITING","sponsor":"Augusta University","startDate":"2022-04-22","conditions":"Chronic Myeloid Leukemia, Chronic Phase, Adult CML, Leukemia, Myeloid","enrollment":100},{"nctId":"NCT04971226","phase":"PHASE3","title":"A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-10-06","conditions":"Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive","enrollment":406},{"nctId":"NCT07454850","phase":"","title":"A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2026-03-17","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":400},{"nctId":"NCT05456191","phase":"PHASE3","title":"A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2022-11-21","conditions":"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia","enrollment":568},{"nctId":"NCT07374120","phase":"","title":"Treatment Patterns and Key Endpoints Among Patients With Chronic-Phase Chronic Myeloid Leukemia in a Community Oncology Setting","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-02-01","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":1480},{"nctId":"NCT03610971","phase":"PHASE2","title":"Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-11-19","conditions":"Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase","enrollment":24},{"nctId":"NCT03874858","phase":"PHASE2","title":"A Study of Full Treatment-free Remission in Patients With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-22","conditions":"Chronic Myeloid Leukemia","enrollment":124},{"nctId":"NCT03817398","phase":"PHASE2","title":"Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2019-11-08","conditions":"Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","enrollment":110},{"nctId":"NCT06427811","phase":"PHASE4","title":"Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2024-11-28","conditions":"Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase","enrollment":85},{"nctId":"NCT04666259","phase":"PHASE3","title":"Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-25","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":56},{"nctId":"NCT06514534","phase":"PHASE2","title":"Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-02-18","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":20},{"nctId":"NCT02917720","phase":"PHASE2","title":"2nd or 3rd TKI-stop After 2 Years Nilotinib Pre-treatment in CML-patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"European LeukemiaNet","startDate":"2016-09","conditions":"Chronic Myeloid Leukemia","enrollment":75},{"nctId":"NCT04258943","phase":"PHASE1, PHASE2","title":"Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-07-06","conditions":"Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia","enrollment":60},{"nctId":"NCT07158294","phase":"NA","title":"Identification of BCR::ABL1 Mutations by Digital PCR in CML","status":"NOT_YET_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2026-02-01","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":150},{"nctId":"NCT07151820","phase":"","title":"A Real-world Study About the Impact of Adverse Events (AEs) on Treatment Adjustments, Healthcare Resource Use, and Costs Among Chronic Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2024-04-08","conditions":"Leukemia, Chronic Myeloid","enrollment":2546},{"nctId":"NCT07150793","phase":"","title":"A Study of Real-world Treatment and Burden of Chronic Myeloid Leukemia Patients in Japan","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2022-07-05","conditions":"Myeloid Leukemia, Chronic","enrollment":754},{"nctId":"NCT07061145","phase":"","title":"A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"Azienda USL Reggio Emilia - IRCCS","startDate":"2025-07-01","conditions":"Chronic Myelocytic Leukemia, Erectile Dysfunctions, CVD - Cardiovascular Disease","enrollment":350},{"nctId":"NCT04838041","phase":"PHASE2","title":"Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation","status":"RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2021-11-11","conditions":"Chronic Phase Chronic Myelogenous Leukemia","enrollment":51},{"nctId":"NCT07091019","phase":"","title":"A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy","status":"NOT_YET_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-11-15","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":1000},{"nctId":"NCT06390306","phase":"","title":"The Efficacy and Safety of Third-generation TKIs Combined With Azacitidine and Bcl-2 Inhibitor in Patients With CML-MBP","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2024-07-01","conditions":"Chronic Myeloid Leukemia","enrollment":30},{"nctId":"NCT05130138","phase":"NA","title":"Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2022-01-27","conditions":"Chronic Myeloid Leukemia","enrollment":100},{"nctId":"NCT06453902","phase":"PHASE2","title":"TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients","status":"RECRUITING","sponsor":"Shenzhen TargetRx Co., Ltd.","startDate":"2024-07-15","conditions":"Chronic Myeloid Leukemia, Accelerated Phase CML","enrollment":40},{"nctId":"NCT04160546","phase":"PHASE2","title":"Study to Evaluate the Reinduction and Second Stop of TKI with Ponatinib in CML in Molecular Response (ResToP)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fundacion CRIS de Investigación para Vencer el Cáncer","startDate":"2020-01-17","conditions":"Chronic Myeloid Leukemia, Chronic Phase","enrollment":80},{"nctId":"NCT04808115","phase":"PHASE1","title":"IIT PH1 KDS-1001 in Patients With CML","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2024-12","conditions":"CML (Chronic Myelogenous Leukemia","enrollment":""},{"nctId":"NCT02326311","phase":"PHASE3","title":"Optimization of TKIs Treatment and Quality of Life in Ph+ CML Patients ≥60 Years in Deep Molecular Response","status":"COMPLETED","sponsor":"Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia","startDate":"2015-06-10","conditions":"Leukemia, Chronic Myeloid","enrollment":229},{"nctId":"NCT02629692","phase":"PHASE1, PHASE2","title":"Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharma Advanced Research Company Limited","startDate":"2016-06-27","conditions":"Healthy (For Part A), Chronic Myeloid Leukemia (for Part B and C)","enrollment":122},{"nctId":"NCT05753384","phase":"PHASE3","title":"Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System","status":"RECRUITING","sponsor":"Poitiers University Hospital","startDate":"2023-12-01","conditions":"Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia","enrollment":140},{"nctId":"NCT03481868","phase":"NA","title":"EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors","status":"RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2018-02-01","conditions":"Chronic Myeloid Leukemia (CML), Chronic Phase","enrollment":160},{"nctId":"NCT02734823","phase":"","title":"Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor","status":"WITHDRAWN","sponsor":"University of Southern California","startDate":"2016-03-01","conditions":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Gastrointestinal Stromal Tumor, Premenopausal","enrollment":""},{"nctId":"NCT04384848","phase":"NA","title":"The EMPATHY Pilot Study","status":"COMPLETED","sponsor":"Northwestern University","startDate":"2019-11-01","conditions":"Leukemia, Chronic Myeloid, Cancer","enrollment":94},{"nctId":"NCT02222272","phase":"","title":"Effect of 2nd Gen TKI in CML","status":"COMPLETED","sponsor":"European Society for Blood and Marrow Transplantation","startDate":"2010-01-01","conditions":"Myeloid Leukemia, Chronic","enrollment":432},{"nctId":"NCT06121765","phase":"","title":"Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2023-11-01","conditions":"CML, Chronic Phase","enrollment":45},{"nctId":"NCT05286528","phase":"","title":"Study to Evaluate Chronic Myeloid Leukemia Treatment Landscape and Real-life Treatment Outcomes in Hungary: Analysis of National Health Insurance Fund Database","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-11-18","conditions":"Chronic Myeloid Leukaemia","enrollment":1484},{"nctId":"NCT04965649","phase":"","title":"Is There an Association Between Innate CD8+ T Cells and the Evolution of Tyrosine Kinase Inhibitor Resistance Mutations in Phi+ Hematological Malignancies.","status":"UNKNOWN","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-01-01","conditions":"Leukemia, Myelogenous Leukemia, Chronic Leukemia","enrollment":30},{"nctId":"NCT05926128","phase":"NA","title":"Study of Treatment Free Remission in Patients With Chronic Myeloid Leukemia in Chronic Phase","status":"UNKNOWN","sponsor":"Fundaleu","startDate":"2019-02-01","conditions":"CML","enrollment":75},{"nctId":"NCT01657604","phase":"PHASE3","title":"TKI and Interferon Alpha Evaluation Initiated by the German Chronic Myeloid Leukemia Study Group - the TIGER Study","status":"COMPLETED","sponsor":"University of Jena","startDate":"2012-08-24","conditions":"Chronic Myeloid Leukemia","enrollment":717},{"nctId":"NCT03117816","phase":"PHASE3","title":"ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission","status":"COMPLETED","sponsor":"Philipps University Marburg","startDate":"2017-05-04","conditions":"Chronic Myeloid Leukemia in Remission","enrollment":214},{"nctId":"NCT02269267","phase":"PHASE2","title":"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-12-18","conditions":"Leukemia, Myeloid, Chronic","enrollment":173},{"nctId":"NCT05743465","phase":"","title":"A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia","status":"COMPLETED","sponsor":"Takeda","startDate":"2021-10-06","conditions":"Leukemia","enrollment":1769},{"nctId":"NCT05367700","phase":"PHASE1","title":"A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.","status":"RECRUITING","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","startDate":"2022-04-28","conditions":"CML, Chronic Phase, CML, Accelerated Phase","enrollment":108},{"nctId":"NCT03885830","phase":"","title":"Precision Dosing of Tyrosine Kinase Inhibitors in CML Patients","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-06-20","conditions":"CML, Chronic Phase, CML (Chronic Myelogenous Leukemia, CML - Philadelphia Chromosome","enrollment":45},{"nctId":"NCT03045120","phase":"","title":"Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-07-19","conditions":"Chronic Phase Chronic Myeloid Leukemia","enrollment":118},{"nctId":"NCT05440747","phase":"","title":"Treatment Free Remission (TFR) in CML Patients （CML-CP）Study","status":"NOT_YET_RECRUITING","sponsor":"Guangdong Provincial People's Hospital","startDate":"2022-07-31","conditions":"Chronic Myeloid Leukemia, Treatment-free Remission","enrollment":203},{"nctId":"NCT01244750","phase":"","title":"Studying First Line Treatment of Chronic Myeloid Leukemia (CML) in a Real-world Setting","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-12-02","conditions":"Chronic Myeloid Leukemia","enrollment":1494},{"nctId":"NCT04274231","phase":"","title":"Cancer-associated Gene Mutations in CML Treatment With TKIs by NGS","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2020-02-16","conditions":"Different Gene Between Different TKIs Effection","enrollment":100},{"nctId":"NCT00769327","phase":"PHASE2","title":"Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2009-02-09","conditions":"Leukemia","enrollment":129},{"nctId":"NCT04769947","phase":"","title":"Italian Treatment Free Remission Registry","status":"RECRUITING","sponsor":"University of Turin, Italy","startDate":"2021-08-09","conditions":"Treatment Free Remission, Chronic Myeloid Leukemia","enrollment":800},{"nctId":"NCT05112653","phase":"","title":"Value of MicroRNA30a in Philadelphia Positive Leukemic Patients","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2022-04-01","conditions":"Possibility of Using microRNA30a as a Prognostic Marker in Philadelphia Positive Leukemic Patients by Measure Level of microRNA30a in Blood Sample","enrollment":70},{"nctId":"NCT01596114","phase":"PHASE3","title":"European Stop Tyrosine Kinase Inhibitor Study","status":"COMPLETED","sponsor":"European LeukemiaNet","startDate":"2012-05-30","conditions":"Chronic Myeloid Leukemia","enrollment":868},{"nctId":"NCT03647215","phase":"","title":"CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey","status":"COMPLETED","sponsor":"Incyte Biosciences UK","startDate":"2017-12-18","conditions":"Chronic Phase Chronic Myelogenous Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia","enrollment":427},{"nctId":"NCT04925141","phase":"PHASE4","title":"A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2016-05-10","conditions":"Chronic Myelogenous Leukemia - Chronic Phase","enrollment":62},{"nctId":"NCT02130557","phase":"PHASE3","title":"A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07-15","conditions":"Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive","enrollment":536},{"nctId":"NCT02638467","phase":"PHASE2","title":"Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy","status":"COMPLETED","sponsor":"University of Milano Bicocca","startDate":"2015-11","conditions":"Leukemia, Myelogenous, Chronic","enrollment":2},{"nctId":"NCT01914484","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2013-08-01","conditions":"Chronic Phase Chronic Myeloid Leukemia, Accelerated Phase Chronic Myeloid Leukemia, Blastic Phase Chronic Myeloid Leukemia","enrollment":4},{"nctId":"NCT04578847","phase":"PHASE2","title":"A Study of REduction And DIscontinuation Treatment of TKI (Imatinib, Nilotinib, Dasatinib and Bosutinib)","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2020-01-15","conditions":"Chronic Myeloid Leukemia, Chronic Myeloid Leukemia in Remission, BCR-ABL Positive Chronic Myelogenous Leukemia","enrollment":100},{"nctId":"NCT03880617","phase":"","title":"Distress, Medication Adherence and Care Needs in Patients With CML and GIST Receiving Oral Targeted Therapy","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-03-25","conditions":"CML, GIST","enrollment":297},{"nctId":"NCT02767063","phase":"PHASE1, PHASE2","title":"Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)","status":"UNKNOWN","sponsor":"Versailles Hospital","startDate":"2016-07","conditions":"Leukemia, Myeloid, Chronic-Phase","enrollment":100},{"nctId":"NCT02923986","phase":"PHASE1, PHASE2","title":"Clinical Trial of BP1001 (Liposomal Grb2 Antisense Oligonucleotide) in Combination With Dasatinib in Patients With Ph + CML Who Have Failed TKI, Ph+ AML, Ph+ MDS","status":"WITHDRAWN","sponsor":"Bio-Path Holdings, Inc.","startDate":"2017-09-01","conditions":"Chronic Myelogenous Leukemia, Ph1-Positive, Acute Myeloid Leukemia, Myelodysplastic Syndrome","enrollment":""},{"nctId":"NCT02906696","phase":"PHASE2","title":"Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-10-28","conditions":"Blasts Under 15 Percent of Bone Marrow Nucleated Cells, Blasts Under 15 Percent of Peripheral Blood White Cells, Blasts Under 30 Percent of Bone Marrow Nucleated Cells","enrollment":8},{"nctId":"NCT03540654","phase":"","title":"Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2016-12-07","conditions":"Hematologic Diseases, Chronic Myeloid Leukemia","enrollment":355},{"nctId":"NCT01460498","phase":"PHASE1","title":"Azacitidine (AZA) in Minimal Residual Disease (MRD) Chronic Myeloid Leukemia (CML)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-08-08","conditions":"Leukemia","enrollment":3},{"nctId":"NCT03907670","phase":"","title":"Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2019-10-01","conditions":"Chronic Phase Chronic Myelogenous Leukemia","enrollment":45},{"nctId":"NCT04104035","phase":"","title":"Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response","status":"UNKNOWN","sponsor":"Ankara University","startDate":"2019-08-13","conditions":"Chronic Myeloid Leukemia","enrollment":100},{"nctId":"NCT03090477","phase":"NA","title":"Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients","status":"COMPLETED","sponsor":"UCSI University","startDate":"2017-03-24","conditions":"Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Medication Adherence","enrollment":129},{"nctId":"NCT02730195","phase":"PHASE2","title":"Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic Myeloid Leukemia","status":"TERMINATED","sponsor":"Emory University","startDate":"2016-05","conditions":"Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive","enrollment":9},{"nctId":"NCT00363649","phase":"PHASE2","title":"Interferon and GM-CSF Compared With Imatinib Mesylate and Vaccine Therapy in Patients With Chronic Phase CML on a TKI","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2006-09","conditions":"Leukemia","enrollment":36},{"nctId":"NCT03573596","phase":"PHASE2","title":"Persistence of MR3 in Chronic Myeloid Leukemia (CML) After a 2nd Stop of TKI Treatment","status":"UNKNOWN","sponsor":"Amsterdam UMC, location VUmc","startDate":"2018-02-01","conditions":"CML, Relapsed","enrollment":134},{"nctId":"NCT02108951","phase":"PHASE3","title":"Study to Assess Efficacy and Safety of Nilotinib 300mg Twice Daily in Patients With Philadelphia Positive Chronic Myeloid Leukaemia (CML) in Chronic Phase Who Are Intolerant to Prior Tyrosine Kinase Inhibitors.","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-07-07","conditions":"Philidelphia Positive Chronic Myeloid Leukaemia","enrollment":20},{"nctId":"NCT01073436","phase":"","title":"Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha","status":"TERMINATED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2009-05","conditions":"Chronic Myeloid Leukemia","enrollment":7},{"nctId":"NCT01188278","phase":"","title":"Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2010-07","conditions":"Leukemia, Myeloid, Chronic-Phase (CML-CP)","enrollment":173},{"nctId":"NCT02733445","phase":"","title":"Metabolic Outcomes in Patients Receiving Tyrosine Kinase Inhibitor (TKI) Therapy With Dasatinib or Nilotinib","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-12","conditions":"Chronic Myeloid Leukemia (CML)","enrollment":2650},{"nctId":"NCT01169753","phase":"NA","title":"Nuvigil in Treatment of Cancer-Related Fatigue in Chronic Myeloid Leukemia Patients","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-05","conditions":"Chronic Myeloid Leukemia","enrollment":1},{"nctId":"NCT01392170","phase":"PHASE2","title":"Pegasys in Patients With Chronic Myeloid Leukemia (CML)","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-10","conditions":"Leukemia","enrollment":2},{"nctId":"NCT01562847","phase":"","title":"Prospective Investigation of Dynamics of ABL Mutations in Imatinib Failed CML Patients Treated With Nilotinib","status":"UNKNOWN","sponsor":"Seoul St. Mary's Hospital","startDate":"2011-07","conditions":"Chronic Myeloid Leukemia","enrollment":125}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"treatment of TKI in CML","genericName":"treatment of TKI in CML","companyName":"Poitiers University Hospital","companyId":"poitiers-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug targets the BCR-ABL protein to inhibit cancer cell growth in chronic myeloid leukemia. Used for Chronic myeloid leukemia (CML) treatment.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}